Insider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Insider Sells 2,007 Shares of Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) insider Xiaodong Wang sold 2,007 shares of BeOne Medicines stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $265.50, for a total transaction of $532,858.50. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Xiaodong Wang also recently made the following trade(s):

• On Tuesday, June 10th, Xiaodong Wang sold 41,760 shares of BeOne Medicines stock. The stock was sold at an average price of $262.82, for a total transaction of $10,975,363.20.
• On Tuesday, May 13th, Xiaodong Wang sold 41,760 shares of BeOne Medicines stock. The shares were sold at an average price of $223.50, for a total transaction of $9,333,360.00.
• On Monday, April 14th, Xiaodong Wang sold 41,760 shares of BeOne Medicines stock. The shares were sold at an average price of $242.66, for a total value of $10,133,481.60.

BeOne Medicines Stock Up 0.1%

Shares of ONC traded up $0.33 during trading on Wednesday, reaching $267.13. The company's stock had a trading volume of 292,986 shares, compared to its average volume of 444,749. The company has a market cap of $29.28 billion, a P/E ratio of -71.81 and a beta of 0.30. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.71 and a current ratio of 1.96. The business's fifty day moving average price is $246.44. BeOne Medicines Ltd. - Sponsored ADR has a twelve month low of $141.31 and a twelve month high of $287.88.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $1.93. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. As a group, equities analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ONC has been the subject of several analyst reports. Wall Street Zen raised BeOne Medicines from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Bank of America raised BeOne Medicines from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $207.00 to $320.00 in a research report on Monday, March 3rd. Macquarie upped their price target on BeOne Medicines from $259.00 to $313.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Guggenheim lifted their price objective on shares of BeOne Medicines from $348.00 to $350.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Finally, Sanford C. Bernstein set a $259.00 target price on shares of BeOne Medicines in a research note on Thursday, March 13th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $319.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.